Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hahahaha Ryan.. we seem to think along the same lines sometimes. And I believe you are 100% correct in your assessment.
Lol yep, so predictable. You can bet that if it were reversed and the milestone payment was in Q1 and we claimed that revenues were up by a higher percentage, all h3ll would break loose. LOL
Q4 Revenue only higher than the following Q1 because of a 1 time milestone payment. Otherwise 20% higher normalized revenues. FACT.
Right, so without that ONE TIME milestone payment, revenues were up 20%. So, in other words, normal revenue increased by 20%. LOLOL.
Hate those pesky facts.
If we are indeed using the second facility, shouldn't we have received a PR by now explicitly stating we can use it? I know Elite plays things close to the chest, but I'd say thats a significant development!
How many shares you rocking Ryan G? Just ticked over 150k myself, gonna save up some powder for awhile and watch from the sidelines for now.
Any idea when we should expect a CC PR? Or the date of the CC for that matter
"Yet Pfizer has also been able to grow its business by developing new drugs, some of which have the potential of becoming big sellers. The most promising of these is a new opioid painkiller that might not be as addictive as Oxycodone. Pfizer reported that the safety formulation of the drug, called ALO-02, was similar to existing painkillers."
Oh, you mean similar to other painkillers already out there? LOL. Isn't that the whole point? Multiple companies trying to make BETTER pain meds that are less abusable/abuse resistant?
Glad Pfizer is agreeing that ALO-02 is on par with all the other pain meds out there that are the problem.
7600 shares @ .1001, slide em over to the strong hand side.
Oh yeah. Got an open order as we speak. Just venting. Think we've had more than enough roadblocks for one company is all.
But I haven't lost faith in JT either. He is, like he's said, here to protect his investment. And by association, ours as well.
You'd think!!!
I mean almost every single product we own or have owned / contracted / whatever, has been affected by some type of negative event. I just find it interesting.
JT probably needs a new bottle of <insert liquor> by now. lol.
Lol. Let me get this straight.
Original Lodrane products randomly pulled by the FDA.
Hydromorphone delayed due to site transfer.
Naltrexone delayed due to site transfer.
All THREE Phentermine products to be affected by supply issues.
LOLOL ANYONE ELSE THINK SOMETHING FISHY IS GOING ON??
I'm still long on the company/stock and haven't sold out but WOW.
The question here is: What is it that makes Elite think their supply is being "wrongfully limited" ? They don't seem like the conspiracy theorist type. Hmm.
I wish fate would reverse itself. i.e. Lodrane re-approval to come back and save the company vs. breaking it down. How ironic would that be?
Black cloud over our heads. And for once, it isn't the FDA. Who knew.
+ Lodrane products to be approved!
Just keep in mind that they've hired what, 3 new people over the last few months. I can't remember at what specific times each joined the company, but don't forget to factor that in to mitigate expectations. Just saying.
ELTP
Agreed.
So.. if we do in fact have the materials on hand to start producing the new Phentermine dosages recently approved (15, 30mg), which seems logical enough since we already make the 37.5mg.. we should be receiving a PR pretty shortly eh?
Naltrexone shouldn't be that far behind.
I guess we'll also be able to see in the coming quarters how much of an impact the new facility has on profits, as far as larger batch sizes goes..
Yep. If its still hanging around these low .11, high .10 levels tomorrow you can bet I'll be snagging some cheap seats once my friggin funds clear. No brainer.
Not sure why everyone is just now noticing that.. Fairly certain that they've mentioned cardiovascular and infection before, though I haven't been aware of any plans/drugs in those areas. Don't think its new information though.
Projecting only a mere 10k revenue increase on a new drug addition is in the "no spin zone" for you?? COME ON. LOL LOL LOL LOL
Sounds good man, A+ DD!
Hopefully its good enough to be sticky-worthy!
Post it, PM it, either, both, anything!
Yep and then one day we'll wake up and see that the Lodranes are back in town. LOL
$$$$$$$$$$$Gravytrain
Psh, I wish. Tack on, what, a year on top of anything Elite does for the stupid FDA to pull their head out of their @$$ and approve something for us.
I'll link you someone who obviously can't.. LOL LOL
http://www.aboutlawsuits.com/embeda-recall-manufacturing-problems-16891/
Manufacturing problems have led to the recall of Embeda, a morphine-based painkiller plagued with production problems over the last year.
+
This is the fourth time in about the last year that there has been a recall for Embeda. The most recent recall was announced by King Pharmaceuticals in a letter sent to customers on November 1, 2010. Again, the drug failed to meet specifications for sustained release of its active ingredient.
= Fail. LOL LOL
http://online.wsj.com/article/SB10001424052748703818204576206642060614596.html
Tomato, tomahtoe =P
Gotta have patience like a serial killer.
Boooom!
Tang, mind PMing me your email? Would like to talk about Elite
It was you that claimed for weeks that Naltrexone would be finalized in September.
It was listed on Friday, nice try!
So frustrating trying to get shares lately.
The writing is, as they say, on the wall!
I guess it could be!
I guess you could try and dispute it. But thats like trying to argue that an Xray patent is related to Elite's microtablet patent application.
LOL LOL.
2 new dosages are approved for Elite's Phentermine per FDA's website. It's indisputable.